Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination of an extended-spectrum penicillin (ureidopenicillin) and a beta-lactamase inhibitor. It provides coverage against Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic bacteria.
## Primary Indications
* Intra-abdominal infections (e.g., appendicitis, peritonitis)
* Hospital-acquired and ventilator-associated pneumonia
* Skin and skin structure infections
* Complicated urinary tract infections
* Empiric treatment of febrile neutropenia
## Adult Dosing
Standard dose is **3.375 g (3 g piperacillin / 0.375 g tazobactam) IV every 6 hours**.
For severe infections (e.g., *Pseudomonas* or nosocomial pneumonia), **4.5 g (4 g piperacillin / 0.5 g tazobactam) IV every 6 hours** is recommended. Doses are typically infused over 4 hours for critically ill patients (extended infusion) to maximize pharmacodynamic target attainment.
## Pediatric Dosing
**Neonates (≤ 2 months):** Dosing is gestational/postnatal age-dependent (refer to institutional neonatology protocols).
**Infants/Children (≥ 2 months):** 80–100 mg/kg of the piperacillin component per dose (up to a maximum of 4 g piperacillin) every 6–8 hours.
## Dose Adjustments
Renal impairment requires dose adjustment based on creatinine clearance (CrCl).
* **CrCl 20–40 mL/min:** 2.25 g every 6 hours.
* **CrCl < 20 mL/min:** 2.25 g every 8 hours.
* **Hemodialysis:** 2.25 g every 8 hours, with an additional 0.75 g dose given after each dialysis session.
* *Note: Always consult local institutional nomograms for exact renal adjustment protocols.*
## Contraindications
* Known hypersensitivity to piperacillin, tazobactam, or any component of the penicillin, cephalosporin, or beta-lactamase inhibitor classes (anaphylaxis risk).
## Adverse Effects
* **Common:** Diarrhea, nausea, constipation, headache, insomnia.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity/anaphylaxis, bone marrow suppression (neutropenia/thrombocytopenia), seizures (especially with high doses/renal impairment).
## Key Drug Interactions
* **Probenecid:** Decreases renal clearance of piperacillin, increasing serum concentrations.
* **Aminoglycosides:** Potential for physical incompatibility; infuse through separate lines.
* **Methotrexate:** Penicillins may decrease renal elimination, increasing methotrexate toxicity risk.
* **Warfarin:** Theoretical increased risk of bleeding due to potential impact on platelet aggregation.
## Monitoring
* **Renal Function:** Monitor serum creatinine and adjust dosage accordingly.
* **Hematologic:** Periodic CBC with differential, especially during prolonged therapy (>14 days), to monitor for neutropenia.
* **Electrolytes:** Monitor for hypokalemia, especially in patients with poor intake or receiving diuretics.
* **C. difficile:** Monitor for frequency of stools/abdominal symptoms.
## Clinical Pearls
* **Stability:** Ensure compatibility with IV fluids; piperacillin/tazobactam is stable in most standard crystalloids but incompatible with many medications in the same syringe/line.
* **Spectrum:** Does not cover MRSA, *Acinetobacter* (variable), or organisms producing certain carbapenemases or ESBLs (though often effective for ESBL clinical outcomes).
* **Extended Infusion:** For severe infections, extended infusions (over 4 hours) are often preferred to ensure serum concentrations remain above the MIC for a greater percentage of the dosing interval.
***
**Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, local institutional guidelines, and compatibility charts before administration. Consult a clinical pharmacist or infectious disease specialist for complex management.
